Provided by Tiger Trade Technology Pte. Ltd.

Edgewise Therapeutics, Inc.

27.29
+5.5525.50%
Post-market: 27.20-0.0900-0.33%15:23 EST
Volume:3.62M
Turnover:94.30M
Market Cap:2.89B
PE:-17.37
High:27.38
Open:22.44
Low:22.16
Close:21.75
52wk High:30.48
52wk Low:10.60
Shares:105.87M
Float Shares:60.53M
Volume Ratio:2.30
T/O Rate:5.98%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.5708
EPS(LYR):-1.4480
ROE:-30.02%
ROA:-20.66%
PB:5.17
PE(LYR):-18.85

Loading ...

Company Profile

Company Name:
Edgewise Therapeutics, Inc.
Exchange:
NASDAQ
Establishment Date:
2017
Employees:
136
Office Location:
1715 38th Street,Boulder,Colorado,United States
Zip Code:
80301
Fax:
- -
Introduction:
Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, EDG-5506, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy. The company also develops EDG-7500, a small molecule for the treatment of hypertrophic cardiomyopathy and other severe cardiac disorders. In addition, it develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. The Company was incorporated in 2017 and is headquartered in Boulder, Colorado.

Directors

Name
Position
Kevin Koch
President, Chief Executive Officer and Director
Alan Russell
Chief Scientific Officer and Director
Peter Thompson
Director and Chairperson
Arlene M. Morris
Director
Badreddin Edris
Director
Christopher Martin
Director
Jonathan Fox
Director
Jonathan Root
Director
Laura Brege
Director

Shareholders

Name
Position
Kevin Koch
President, Chief Executive Officer and Director
Robert Blaustein
Chief Operating Officer
Michael Nofi
Chief Financial Officer
Alan Russell
Chief Scientific Officer and Director
Behrad Derakhshan
Chief Business Officer
Joanne M. Donovan
Chief Medical Officer
John Moore
General Counsel